Serum eosinophil cationic protein (ECP) as a mediator of inflammation in acute asthma, during resolution and during the monitoring of stable asthmatic patients treated with inhaled steroids according to a dose reduction schedule

Inflammation Research

Volumn 48, Issue 2, 1999, Pages 94-100

  Kunkel, G ^a   Ryden A C ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b PFIZER INC   (United States)

Author keywords

Acute asthma; ECP; Inflammation mediators; MPO; Steroid reduction

Indexed keywords

AUTACOID; EOSINOPHIL CATIONIC PROTEIN; MYELOPEROXIDASE; STEROID;

ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; SPIROMETRY;

EID: 0033056313     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050425     Document Type: Article

References (21)

1. Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
2. Venge P. Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma. Clin Exp Allergy 1993;23 Suppl 2:3-7.
3. Ahlstedt S, Enander I, Peterson CGB, Lanner Å. The clinical assessment of the inflammatory component in asthma with emphasis on the eosinophils. Pract Allergy Immunol 1993;8:149-54.
4. Ädelroth E, Rosenhall L, Johansson SÅ, Linden M, Venge P. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: The effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 1990;142:91-9.
5. Bousquet J, Chanex P, Lacoste JY, Enander I, Venge P, Peterson C, et al. Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. J Allergy Clin Immunol 1991;88:649-60.
6. Pizzichini E, Pizzichini MMM, Efthimiadis A, Evans S, Morris MM, Squillace D, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308-17.
7. Zimmerman B, Tsui F. Can the measurement of scrum ECP be used to monitor treatment of childhood asthma with inhaled steroid? Allergy 1993;48:129-32.
8. Zimmerman B, Lanner A, Enander I, Zimmerman RS, Peterson CGB, Ahlstedt S. Total eosinophils, serum eosinophilic cationic protein and eosinophil protein X in childhood asthma: Relation to disease status and therapy. Clin Exp Allergy 1993;23:564-70.
9. Parra A, Prieto I, Sanz ML, Dieguz I, Resano A, Oehling AK. Serum ECP levels in asthmatic patients: Comparison with other follow-up parameters. Allergy Asthma Proc 1996;17:191-7.
10. 20 and exacerbations. Respir Med 1994;88:613-21.
11. Griffin E, Håkansson L, Formgren H, Jörgensen K, Peterson C, Venge P. Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia. J Allergy Clin Immunol 1991;87:5548-57.
12. Venge P. Eosinophil activity in bronchial asthma. Allergy Proc 1994;15:139-41.
13. Karawajczyk M, Pauksen K, Peterson CGB, Eklund E, Venge P. The differential release of eosinophil granule proteins. Studies on patients with acute bacterial and viral infections. Clin Exp Allergy 1995;25:713-9.
14. Jennings BH, Andersson KE, Johansson SÅ. Assessment of systemic effects of inhaled glucocorticosteroids: Comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991;40:77-82.
15. Wever AMJ, Wever-Hess J, Hermans J. The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma. Clin Exp Allergy 1997;27:519-29.
16. Marks GB, Kjellerby J, Luczynska CM, Burney PGJ. Serum eosinophil cationic protein distribution and reproducibility in a random sample of men. Am J Respir Crit Care Med 1997; 155:A80.
17. Wever AMJ, Wever-Hess J, Dahl R. Use of assessment of inflammation in management of drug therapy in asthma. Clin Immunother 1995;4:462-70.
18. Chapman ID, Foster A, Morley J. The relationship between inflammation and hyperreactivity of the airways in asthma. Clin Exp Allergy 1993;23:168-71.
19. Jupiter EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: A randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991;87:483-9.
20. Hedlin G, Ahlstedt S, Håkansson L, Venge P. Eosinophil cationic protein (ECP), eosinophil chemotactic activity (ECA), neutrophil chemotactic activity (NCA) and tryptase in serum before and during bronchial challenge in cat-allergic children with asthma. Pediatr Allergy Immunol 1992;3:144-9.
21. Zimmerman B, Enander I, Zimmerman R, Ahlstedt S. Asthma in children less than 5 years of age: Eosinophils and serum levels of the cationic proteins ECP and EPX in relation to atopy and symptoms. Clin Exp Allergy 1994;21:149-55.